REFERENCES
1. Goedert M, Jakes R, Spillantini MG. The synucleinopathies: twenty years on. J Parkinsons Dis. 2017;7:S51-69.
2. Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of synucleinopathies. Mol Neurodegener. 2021;16:83.
3. Li W, Li JY. Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration. Transl Neurodegener. 2024;13:16.
4. Choi ML, Chappard A, Singh BP, et al. Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity. Nat Neurosci. 2022;25:1134-48.
5. Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm. 1988;74:199-205.
6. Chen Q, Chen Y, Zhang Y, et al. Iron deposition in Parkinson’s disease by quantitative susceptibility mapping. BMC Neurosci. 2019;20:23.
7. Castellani RJ, Siedlak SL, Perry G, Smith MA. Sequestration of iron by Lewy bodies in Parkinson’s disease. Acta Neuropathol. 2000;100:111-4.
8. Neumann M, Adler S, Schlüter O, Kremmer E, Benecke R, Kretzschmar HA. Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol. 2000;100:568-74.
9. Indi SS, Rao KS. Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study. Neurosci Lett. 2007;424:78-82.
10. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure. J Biol Chem. 2001;276:44284-96.
11. Peng Y, Wang C, Xu HH, Liu YN, Zhou F. Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes. J Inorg Biochem. 2010;104:365-70.
13. Zhao Q, Tao Y, Zhao K, et al. Structural insights of Fe3+ induced α-synuclein fibrillation in Parkinson’s disease. J Mol Biol. 2023;435:167680.
14. Golts N, Snyder H, Frasier M, Theisler C, Choi P, Wolozin B. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J Biol Chem. 2002;277:16116-23.
15. Binolfi A, Rasia RM, Bertoncini CW, et al. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J Am Chem Soc. 2006;128:9893-901.
16. Bharathi, Rao KSJ. Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson’s disease. Biochem Biophys Res Commun. 2007;359:115-20.
17. Kostka M, Högen T, Danzer KM, et al. Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J Biol Chem. 2008;283:10992-1003.
18. Abeyawardhane DL, Fernández RD, Murgas CJ, et al. Iron redox chemistry promotes antiparallel oligomerization of α-synuclein. J Am Chem Soc. 2018;140:5028-32.
19. Bonadonna M, Altamura S, Tybl E, et al. Iron regulatory protein (IRP)-mediated iron homeostasis is critical for neutrophil development and differentiation in the bone marrow. Sci Adv. 2022;8:eabq4469.
20. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci. 2004;1012:1-13.
21. Zhou ZD, Tan EK. Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases. Mol Neurodegener. 2017;12:75.
22. Kato J, Kobune M, Ohkubo S, et al. Iron/IRP-1-dependent regulation of mRNA expression for transferrin receptor, DMT1 and ferritin during human erythroid differentiation. Exp Hematol. 2007;35:879-87.
23. Salvatore MF, Fisher B, Surgener SP, Gerhardt GA, Rouault T. Neurochemical investigations of dopamine neuronal systems in iron-regulatory protein 2 (IRP-2) knockout mice. Brain Res Mol Brain Res. 2005;139:341-7.
24. LaVaute T, Smith S, Cooperman S, et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet. 2001;27:209-14.
25. Febbraro F, Giorgi M, Caldarola S, Loreni F, Romero-Ramos M. α-Synuclein expression is modulated at the translational level by iron. Neuroreport. 2012;23:576-80.
26. Cahill CM, Lahiri DK, Huang X, Rogers JT. Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochim Biophys Acta. 2009;1790:615-28.
27. Qu L, Xu H, Jia W, Jiang H, Xie J. Rosmarinic acid protects against MPTP-induced toxicity and inhibits iron-induced α-synuclein aggregation. Neuropharmacology. 2019;144:291-300.
28. Rogers JT, Mikkilineni S, Cantuti-Castelvetri I, et al. The alpha-synuclein 5′untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. J Neural Transm. 2011;118:493-507.
29. Olivares D, Huang X, Branden L, Greig NH, Rogers JT. Physiological and pathological role of alpha-synuclein in Parkinson’s disease through iron mediated oxidative stress; the role of a putative iron-responsive element. Int J Mol Sci. 2009;10:1226-60.
30. Gabrielyan L, Liang H, Minalyan A, Hatami A, John V, Wang L. Behavioral deficits and brain α-synuclein and phosphorylated serine-129 α-synuclein in male and female mice overexpressing human α-synuclein. J Alzheimers Dis. 2021;79:875-93.
31. Wang R, Wang Y, Qu L, et al. Iron-induced oxidative stress contributes to α-synuclein phosphorylation and up-regulation via polo-like kinase 2 and casein kinase 2. Neurochem Int. 2019;125:127-35.
32. Borgo C, D’Amore C, Sarno S, Salvi M, Ruzzene M. Protein kinase CK2: a potential therapeutic target for diverse human diseases. Signal Transduct Target Ther. 2021;6:183.
33. Cheng J, Wu L, Chen X, et al. Polo-like kinase 2 promotes microglial activation via regulation of the HSP90α/IKKβ pathway. Cell Rep. 2024;43:114827.
34. Waxman EA, Giasson BI. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol. 2008;67:402-16.
35. Inglis KJ, Chereau D, Brigham EF, et al. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem. 2009;284:2598-602.
36. Lu Y, Prudent M, Fauvet B, Lashuel HA, Girault HH. Phosphorylation of α-synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of α-synuclein in the pathogenesis of Parkinson’s disease and related disorders. ACS Chem Neurosci. 2011;2:667-75.
37. Liu LL, Franz KJ. Phosphorylation-dependent metal binding by alpha-synuclein peptide fragments. J Biol Inorg Chem. 2007;12:234-47.
38. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem. 2003;278:25009-13.
39. Xilouri M, Brekk OR, Stefanis L. α-Synuclein and protein degradation systems: a reciprocal relationship. Mol Neurobiol. 2013;47:537-51.
40. Petroi D, Popova B, Taheri-Talesh N, et al. Aggregate clearance of α-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome. J Biol Chem. 2012;287:27567-79.
41. Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci. 2004;24:1888-96.
42. Poehler AM, Xiang W, Spitzer P, et al. Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment. Autophagy. 2014;10:2171-92.
43. Haj-Yahya M, Fauvet B, Herman-Bachinsky Y, et al. Synthetic polyubiquitinated α-synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. Proc Natl Acad Sci U S A. 2013;110:17726-31.
44. Sahoo S, Padhy AA, Kumari V, Mishra P. Role of ubiquitin-proteasome and autophagy-lysosome pathways in α-synuclein aggregate clearance. Mol Neurobiol. 2022;59:5379-407.
45. Wan W, Jin L, Wang Z, et al. Iron deposition leads to neuronal α-synuclein pathology by inducing autophagy dysfunction. Front Neurol. 2017;8:1.
46. Wang Y, Wang M, Liu Y, et al. Integrated regulation of stress responses, autophagy and survival by altered intracellular iron stores. Redox Biol. 2022;55:102407.
47. Ott C, König J, Höhn A, Jung T, Grune T. Reduced autophagy leads to an impaired ferritin turnover in senescent fibroblasts. Free Radic Biol Med. 2016;101:325-33.
48. Rinaldi DE, Corradi GR, Cuesta LM, Adamo HP, de Tezanos Pinto F. The Parkinson-associated human P5B-ATPase ATP13A2 protects against the iron-induced cytotoxicity. Biochim Biophys Acta. 2015;1848:1646-55.
49. Prakash J, Schmitt SM, Dou QP, Kodanko JJ. Inhibition of the purified 20S proteasome by non-heme iron complexes. Metallomics. 2012;4:174-8.
50. Bordini J, Morisi F, Cerruti F, et al. Iron causes lipid oxidation and inhibits proteasome function in multiple myeloma cells: a proof of concept for novel combination therapies. Cancers. 2020;12:970.
51. Nurtjahja-Tjendraputra E, Fu D, Phang JM, Richardson DR. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood. 2007;109:4045-54.
52. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060-72.
53. Katsarou A, Pantopoulos K. Basics and principles of cellular and systemic iron homeostasis. Mol Aspects Med. 2020;75:100866.
54. Chifman J, Laubenbacher R, Torti SV. A systems biology approach to iron metabolism. In: Corey SJ, Kimmel M, Leonard JN, editors. A systems biology approach to blood. New York: Springer; 2014. pp. 201-25.
55. MacKenzie EL, Iwasaki K, Tsuji Y. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal. 2008;10:997-1030.
56. Taboy CH, Vaughan KG, Mietzner TA, Aisen P, Crumbliss AL. Fe3+ coordination and redox properties of a bacterial transferrin. J Biol Chem. 2001;276:2719-24.
57. Bogdan AR, Miyazawa M, Hashimoto K, Tsuji Y. Regulators of iron homeostasis: new players in metabolism, cell death, and disease. Trends Biochem Sci. 2016;41:274-86.
58. Mao H, Zhao Y, Li H, Lei L. Ferroptosis as an emerging target in inflammatory diseases. Prog Biophys Mol Biol. 2020;155:20-8.
59. Endale HT, Tesfaye W, Mengstie TA. ROS induced lipid peroxidation and their role in ferroptosis. Front Cell Dev Biol. 2023;11:1226044.
60. Xu YY, Wan WP, Zhao S, Ma ZG. L-type calcium channels are involved in iron-induced neurotoxicity in primary cultured ventral mesencephalon neurons of rats. Neurosci Bull. 2020;36:165-73.
61. Wang Y, Tang B, Zhu J, et al. Emerging mechanisms and targeted therapy of ferroptosis in neurological diseases and neuro-oncology. Int J Biol Sci. 2022;18:4260-74.
62. Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014;2014:360438.
63. Mortensen MS, Ruiz J, Watts JL. Polyunsaturated fatty acids drive lipid peroxidation during ferroptosis. Cells. 2023;12:804.
64. Zhang W, Liu Y, Liao Y, Zhu C, Zou Z. GPX4, ferroptosis, and diseases. Biomed Pharmacother. 2024;174:116512.
65. Xue Q, Yan D, Chen X, et al. Copper-dependent autophagic degradation of GPX4 drives ferroptosis. Autophagy. 2023;19:1982-96.
66. Wu K, Yan M, Liu T, et al. Creatine kinase B suppresses ferroptosis by phosphorylating GPX4 through a moonlighting function. Nat Cell Biol. 2023;25:714-25.
67. Weaver K, Skouta R. The selenoprotein glutathione peroxidase 4: from molecular mechanisms to novel therapeutic opportunities. Biomedicines. 2022;10:891.
68. Lingor P, Carboni E, Koch JC. Alpha-synuclein and iron: two keys unlocking Parkinson’s disease. J Neural Transm. 2017;124:973-81.
69. Bi M, Du X, Jiao Q, Liu Z, Jiang H. α-Synuclein regulates iron homeostasis via preventing parkin-mediated DMT1 ubiquitylation in Parkinson’s disease models. ACS Chem Neurosci. 2020;11:1682-91.
70. Perfeito R, Lázaro DF, Outeiro TF, Rego AC. Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells. Mol Cell Neurosci. 2014;62:51-9.
71. Mahoney-Sanchez L, Bouchaoui H, Boussaad I, et al. Alpha synuclein determines ferroptosis sensitivity in dopaminergic neurons via modulation of ether-phospholipid membrane composition. Cell Rep. 2022;40:111231.
72. Angelova PR, Choi ML, Berezhnov AV, et al. Alpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid peroxidation. Cell Death Differ. 2020;27:2781-96.
73. Sarchione A, Marchand A, Taymans JM, Chartier-Harlin MC. Alpha-Synuclein and lipids: the elephant in the room? Cells. 2021;10:2452.
74. Lv QK, Tao KX, Yao XY, et al. Melatonin MT1 receptors regulate the Sirt1/Nrf2/Ho-1/Gpx4 pathway to prevent α-synuclein-induced ferroptosis in Parkinson’s disease. J Pineal Res. 2024;76:e12948.
75. Su Y, Jiao Y, Cai S, Xu Y, Wang Q, Chen X. The molecular mechanism of ferroptosis and its relationship with Parkinson’s disease. Brain Res Bull. 2024;213:110991.
76. Zhou M, Xu K, Ge J, et al. Targeting ferroptosis in Parkinson’s disease: mechanisms and emerging therapeutic strategies. Int J Mol Sci. 2024;25:13042.
77. Devos D, Labreuche J, Rascol O, et al; FAIRPARK-II Study Group. Trial of deferiprone in Parkinson’s disease. N Engl J Med. 2022;387:2045-55.
78. Devos D, Moreau C, Devedjian JC, et al. Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. Antioxid Redox Signal. 2014;21:195-210.
79. Martin-Bastida A, Ward RJ, Newbould R, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease. Sci Rep. 2017;7:1398.
80. Carboni E, Tatenhorst L, Tönges L, et al. Deferiprone rescues behavioral deficits induced by mild iron exposure in a mouse model of alpha-synuclein aggregation. Neuromolecular Med. 2017;19:309-21.
81. Zhu D, Liang R, Liu Y, et al. Deferoxamine ameliorated Al(mal)3-induced neuronal ferroptosis in adult rats by chelating brain iron to attenuate oxidative damage. Toxicol Mech Methods. 2022;32:530-41.
82. Kuo KH, Mrkobrada M. A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia. Hemoglobin. 2014;38:409-21.
83. Zeng X, An H, Yu F, et al. Benefits of iron chelators in the treatment of Parkinson’s disease. Neurochem Res. 2021;46:1239-51.
84. Cukierman DS, Pinheiro AB, Castiñeiras-Filho SL, et al. A moderate metal-binding hydrazone meets the criteria for a bioinorganic approach towards Parkinson’s disease: therapeutic potential, blood-brain barrier crossing evaluation and preliminary toxicological studies. J Inorg Biochem. 2017;170:160-8.
85. Cukierman DS, Lázaro DF, Sacco P, et al. X1INH, an improved next-generation affinity-optimized hydrazonic ligand, attenuates abnormal copper(I)/copper(II)-α-Syn interactions and affects protein aggregation in a cellular model of synucleinopathy. Dalton Trans. 2020;49:16252-67.
86. Ward RJ, Dexter DT, Martin-Bastida A, Crichton RR. Is chelation therapy a potential treatment for Parkinson’s disease? Int J Mol Sci. 2021;22:3338.
87. Todorich B, Pasquini JM, Garcia CI, Paez PM, Connor JR. Oligodendrocytes and myelination: the role of iron. Glia. 2009;57:467-78.
88. Sandoval TA, Salvagno C, Chae CS, et al. Iron chelation therapy elicits innate immune control of metastatic ovarian cancer. Cancer Discov. 2024;14:1901-21.
